Möchten Sie immer auf dem neuesten Stand bleiben?

ASTRAZENECA AND VALEANT PHARMACEUTICALS TO PARTNER ON BRODALUMAB AstraZeneca continues to sharpen focus on main therapy areas as collaboration with expert in dermatology is expected to accelerate...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 28 August 2015, Pascal Soriot, a Director of the Company, notified us that, on 25 August 2015, he purchased...

ASTRAZENECA APPOINTS DR SEAN BOHEN AS EXECUTIVE VICE PRESIDENT OF GLOBAL MEDICINES DEVELOPMENT AND CHIEF MEDICAL OFFICER AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as...

30 July 2015 H1 2015 Results Financial Summary +---------------------+------+----+------++-----+----+------+ | |H1 2015 ||Q2 2015 ...

Utvecklingen i sammandrag +-------------------+--------+---------------+-------+-+--------+-------------- -+-------+ | | Första | | Andra | | ...

AstraZeneca Half Year Results 2015 Tomorrow, Thursday, 30 July 2015, AstraZeneca will release half year results for 2015 at 07:00 bst. An analyst presentation of the half year results will take...

AstraZeneca PLC (the "Company") today confirmed that the intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme announced on 26 June 2015 has now...

AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine. Caprelsa was granted Orphan Drug Designation by the...

27 July 2015 AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine. Caprelsa was granted Orphan Drug...

+-------------++++--------------+ | | +-------------++++--------------+ |TR-1: | |NOTIFICATION | |OF MAJOR ...